NCT05742867Completed
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
Patient Preferences of Treatment for the Patients Suffering From Muscle-invasive Urothelial Carcinoma of Bladder Following Radical Cystectomy in Japan
Source: ClinicalTrials.gov · Last updated 23 Jan 2025
Brief summary (registry, in English)
The main purpose of this study is to identify important treatment attributes for post-radical cystectomy (RC) treatment for participants with MIBC (Muscle-Invasive Bladder Cancer) and assess the relative importance of treatment attributes for post-RC treatment in Japan.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 115 (actual)
- First submitted
- 1 Feb 2023
- Start date
- 31 May 2023
- Primary completion date
- 10 Jul 2024
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Bladder cancer
- NCT number
- NCT05742867
What you commit to
- Study type: Observational
- Participants enrolled: 115
- From 31 May 2023 to the primary completion date, 10 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Determined by the physician as being unsuitable for the study (e.g. having any clinically significant psychiatric disorder, cognitive impairment, or having difficulty with communicating in Japanese)
- Confirmed diagnosis of other primary cancers at the time of obtaining consent
Other
- Current participation in a MIBC clinical trial
Who the study is looking for
- Must reside in Japan and able to speak/read Japanese for the interview/survey
- Must have a clinical diagnosis of Muscle-invasive bladder cancer (MIBC):
- ypT2-ypT4a or ypN+ MIBC, with prior neoadjuvant cisplatin chemotherapy and underwent radical cystectomy
- pT3-pT4a or pN+ MIBC, without prior neoadjuvant cisplatin chemotherapy and underwent radical cystectomy
- Must not have received any treatment related to MIBC after radical cystectomy
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Morrisville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.